Abstract
Objective: To evaluate laboratory criteria for menopause in women taking oral contraceptives (OC). Design: Prospective, uncontrolled pilot study. Setting: San Francisco General Hospital, San Francisco, California, and Magee-Womens Hospital, Pittsburgh, Pennsylvania. Patients: Twenty-eight menopausal women. Interventions: Fourteen menopausal women received triphasic 35 μg ethinyl E2 and 180-215-250 μg norgestimate, and 14 menopausal women received monophasic 30 μg ethinyl E2150 μg desogestrel. Main Outcome Measures: Serum FSH, LH, and E2 levels were evaluated on days 14 and 28 (day 7 of the pill-free interval) of the third cycle of pills. Results: Twelve women in each group completed the study. Fifteen (62.5%) subjects still had a serum FSH <30 mIU/mL (30 IU/L) on the 7th day of the pill-free interval of the third pill package. All subjects had a serum FSH:LH ratio >1 and 20 of 21 (95%) subjects had E2 < 20 pg/mL (73 pmol/L) at the end of the pill-free interval of the third cycle. Conclusions: Measuring FSH on the 7th day of the pill-free interval is not a sensitive test for menopause. Serum FSH:LH ratio >1 or E2 < 20 pg/mL (73 pmol/L) on the 7th day of the pill-free interval may be a more appropriate marker of menopause in women using OC in the later reproductive years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 101-104 |
| Number of pages | 4 |
| Journal | Fertility and Sterility |
| Volume | 66 |
| Issue number | 1 |
| State | Published - 1996 |
| Externally published | Yes |
Fingerprint
Keywords
- E
- FSH
- LH
- menopause
- Oral contraceptives
ASJC Scopus subject areas
- Obstetrics and Gynecology
Cite this
Laboratory criteria for menopause in women using oral contraceptives. / Creinin, Mitchell D.
In: Fertility and Sterility, Vol. 66, No. 1, 1996, p. 101-104.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Laboratory criteria for menopause in women using oral contraceptives
AU - Creinin, Mitchell D
PY - 1996
Y1 - 1996
N2 - Objective: To evaluate laboratory criteria for menopause in women taking oral contraceptives (OC). Design: Prospective, uncontrolled pilot study. Setting: San Francisco General Hospital, San Francisco, California, and Magee-Womens Hospital, Pittsburgh, Pennsylvania. Patients: Twenty-eight menopausal women. Interventions: Fourteen menopausal women received triphasic 35 μg ethinyl E2 and 180-215-250 μg norgestimate, and 14 menopausal women received monophasic 30 μg ethinyl E2150 μg desogestrel. Main Outcome Measures: Serum FSH, LH, and E2 levels were evaluated on days 14 and 28 (day 7 of the pill-free interval) of the third cycle of pills. Results: Twelve women in each group completed the study. Fifteen (62.5%) subjects still had a serum FSH <30 mIU/mL (30 IU/L) on the 7th day of the pill-free interval of the third pill package. All subjects had a serum FSH:LH ratio >1 and 20 of 21 (95%) subjects had E2 < 20 pg/mL (73 pmol/L) at the end of the pill-free interval of the third cycle. Conclusions: Measuring FSH on the 7th day of the pill-free interval is not a sensitive test for menopause. Serum FSH:LH ratio >1 or E2 < 20 pg/mL (73 pmol/L) on the 7th day of the pill-free interval may be a more appropriate marker of menopause in women using OC in the later reproductive years.
AB - Objective: To evaluate laboratory criteria for menopause in women taking oral contraceptives (OC). Design: Prospective, uncontrolled pilot study. Setting: San Francisco General Hospital, San Francisco, California, and Magee-Womens Hospital, Pittsburgh, Pennsylvania. Patients: Twenty-eight menopausal women. Interventions: Fourteen menopausal women received triphasic 35 μg ethinyl E2 and 180-215-250 μg norgestimate, and 14 menopausal women received monophasic 30 μg ethinyl E2150 μg desogestrel. Main Outcome Measures: Serum FSH, LH, and E2 levels were evaluated on days 14 and 28 (day 7 of the pill-free interval) of the third cycle of pills. Results: Twelve women in each group completed the study. Fifteen (62.5%) subjects still had a serum FSH <30 mIU/mL (30 IU/L) on the 7th day of the pill-free interval of the third pill package. All subjects had a serum FSH:LH ratio >1 and 20 of 21 (95%) subjects had E2 < 20 pg/mL (73 pmol/L) at the end of the pill-free interval of the third cycle. Conclusions: Measuring FSH on the 7th day of the pill-free interval is not a sensitive test for menopause. Serum FSH:LH ratio >1 or E2 < 20 pg/mL (73 pmol/L) on the 7th day of the pill-free interval may be a more appropriate marker of menopause in women using OC in the later reproductive years.
KW - E
KW - FSH
KW - LH
KW - menopause
KW - Oral contraceptives
UR - http://www.scopus.com/inward/record.url?scp=0029992925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029992925&partnerID=8YFLogxK
M3 - Article
C2 - 8752618
AN - SCOPUS:0029992925
VL - 66
SP - 101
EP - 104
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 1
ER -